Akademik Veri Yönetim Sistemi
ERS Congress 2025 , Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2025, ss.2076, (Özet Bildiri)
Chronic respiratory failure is a serious condition, especially in COPD and bronchiectasis. LTOT and HMV help manage symptoms, improve quality of life, and reduce hospitalizations. However, patient selection and adherence remain uncertain.
This study evaluates the demographic and clinical characteristics of LTOT and HMV patients in Turkey through a multicenter prospective study. Conducted between October 2023 and February 2025 in 20 centers, data were collected via an online platform.
A total of 273 patients (67% male, mean age 69±12 years) were included. Most (93%) lived with caregivers, while 3% lived alone or in nursing homes. Smoking history was present in 73%, with 30% exposed to biomass fuels and 19% to occupational hazards. Vaccination rates were low: 14% for influenza, 17% for pneumococcus, and 79% for COVID-19. Educational levels varied, with 18% having no formal education and 4% holding university degrees. Functionally, 36% had severe and 57% moderate limitations, with a median mMRC score of 4. Blood gas analysis showed PaO₂ of 51±12 mmHg and PaCO₂ of 52±12 mmHg, improving with oxygen therapy. Pulmonary function tests indicated severe impairment (FEV1: 39%). Comorbidities included hypertension (53%) and diabetes (27%). Treatments included LTOT (50.5%), NIV (22%), NIV+oxygen (19%), and IMV (1.8%). Healthcare professionals provided device training in 86% of cases.
This study presents real-world data on Turkish LTOT and HMV patients, highlighting significant pulmonary impairment and comorbidities. Findings may help optimize home respiratory care services.